DRN の nNOS から SERT を分離することによって,急速発症の抗うつ剤の設計
Nan Sun1,2, Ya-Juan Qin3, Chu Xu1,4
1State Key Laboratory of Reproductive Medicine, Department of Clinic Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.
Science (New York, N.Y.)
|October 27, 2022
まとめ
研究者はセロトニントランスポーター (SERT) と神経酸化窒素合成酵素 (nNOS) の相互作用を標的とした新しい抗うつ剤を開発しました. このアプローチはセロトニンの信号伝達を強化することで 鬱のような行動を 迅速に緩和します
科学分野:
- 神経科学
- 薬理学について
- 分子生物学
背景:
- 重度のうつ病 (MDD) は,限られた迅速な治療法を持つ一般的な精神疾患です.
- 背中のラフェ核 (DRN) は,気分とストレス反応を調節する上で重要な役割を果たします.
- DRNにおけるセロトニントランスポーター (SERT) とニューロン酸化窒素合成酵素 (nNOS) の相互作用は,うつ病の行動に関与しています.
研究 の 目的:
- 鬱病のような表型の発現におけるDRNにおけるSERT-nNOS複合体の役割を調査する.
- 新種の小分子化合物を特定し 評価する 迅速な抗うつ効果
主な方法:
- 慢性的な予測不可能な軽度のストレス (CMS) のマウスモデルを利用して,うつ病のような行動を誘発した.
- DRNにおける SERT-nNOS複合体の形成を評価した.
- 小分子化合物 (ZZL-7) を投与し,その抗うつ薬の効能と副作用を評価した.
主要な成果:
- 慢性的な予測不可能な軽度のストレス (CMS) は選択的にマウスのDRNにおけるSERT- nNOS複合体を増加させた.
- 増加したSERT-nNOS相互作用は 鬱のような行動を再現した.
- ZZL-7を用いてSERT- nOSの相互作用を妨害すると,2時間以内に迅速な抗うつ効果が生じた.
- ZZL-7は有意な副作用なしに有効性を示しました.
結論:
- DRNにおける SERT-nOSの相互作用は,ストレス誘発型うつ病の主要な要因である.
- この相互作用を妨害することは 迅速に作用する抗うつ剤の開発に 有望な戦略です
- ZZL-7はMDDに対する新たな治療薬であり,迅速に発症し,安全性も良好です.
関連する概念動画
01:23Antidepressant Drugs: MAOIs and Other Agents
307
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
307
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
524
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
524
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
374
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
374
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
01:25Antidepressant Drugs: Overview
688
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
688
01:28Structure-Activity Relationships and Drug Design
959
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
959